Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 1, 2009, Pages 167-169

  Pea, Federico ^a   Viale, Pierluigi ^a   Lugano, Manuela ^a   Baccarani, Umberto ^a   Pavan, Federica ^a   Tavio, Marcello ^a   Adani, Gian Luigi ^a   Della Rocca, Giorgio ^a   Furlanut, Mario ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Bile; Cholangitis; Pharmacokinetics; Trough concentration; VRE

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; AGED; ARTICLE; BILE DUCT; CLINICAL ARTICLE; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG PENETRATION; ENTEROCOCCAL INFECTION; FEMALE; GRAM POSITIVE COCCI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL INFECTION; HUMAN; LIVER TRANSPLANTATION; MALE; MULTIDRUG RESISTANCE; PHARMACODYNAMICS; STEADY STATE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BILE DUCTS; CHOLANGITIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OXAZOLIDINONES; PLASMA; VANCOMYCIN RESISTANCE;

EID: 57649166546     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn442     Document Type: Article

References (14)

1. Pea F, Viale P. Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections. Expert Rev Anti Infect Ther 2007; 5: 255-70.
2. Tanaka A, Takada T, Kawarada Y et al. Antimicrobial therapy for acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14: 59-67.
3. Nusair A, Jourdan D, Medcalf S et al. Infection control experience in a cooperative care center for transplant patients. Infect Control Hosp Epidemiol 2008; 29: 424-9.
4. Linden PK, Miller CB. Vancomycin-resistant enterococci: The clinical effect of a common nosocomial pathogen. Diagn Microbiol Infect Dis 1999; 33: 113-20.
5. Gridelli B, Panarello G, Salvatore G et al. Infections after living-donor liver transplantation. Surg Infect (Larchmt) 2006; 7 Suppl 2: S105-8.
6. Mlynarczyk G, Grzybowska W, Mlynarczyk A et al. Significant increase in the isolation of glycopeptide-resistant enterococci from patients hospitalized in the transplant surgery ward in 2004-2005. Transplant Proc 2007; 39: 2883-5.
7. Hoffmeister B, Ockenga J, Schachschal G et al. Rapid development of secondary sclerosing cholangitis due to vancomycin-resistant enterococci. J Infect 2007; 54: E65-8.
8. Andes D, van Ogtrop ML, Peng J et al. In vivo pharmaco-dynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46: 3484-9.
9. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl 2: Ii17-25.
10. Rayner CR, Forrest A, Meagher AK et al. Clinical pharmaco-dynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23.
11. Pea F, Viale P, Lugano M et al. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemo-filtration: A report of 2 cases. Am J Kidney Dis 2004; 44: 1097-102.
12. Jones RN, Fritsche TR, Sader HS et al. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: An activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 2007; 59: 199-209.
13. Pea F, Scudeller L, Lugano M et al. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 2006; 42: 434-5.
14. Plock N, Buerger C, Joukhadar C et al. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos 2007; 35: 1816-23.